Skip to Main Content

While investors may have cheered the recent $74 billion bid that Bristol-Myers Squibb (BMY) made for Celgene (CELG), a pair of Congressional lawmakers want federal authorities to examine the extent to which such a deal may impede competition or cause higher drug prices for Americans.

In a letter sent last Friday to the Federal Trade Commission and the Department of Justice, Rep. Peter Welch (D-Vt.) and Rep. Francis Rooney (R-Fla.) expressed concern that the takeover could reduce treatment options for patients by giving Bristol-Myers access to product lines that may either compete with or complement its current portfolio of cancer drugs.


And they also suggested Bristol-Myers will gain added leverage for negotiating placement of the medicines on formularies, which are the lists of drugs that receive favorable coverage by health plans, or offering discounts. “The larger the company, the more it can use ‘rebate walls’ to block formularies access to more affordable and or equally effective substitute products,” they wrote.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • The fact that I can make a comment on this article for free, but have to pay to read it, means that anyone can make a biased, untrue, crazy opinionated comment to try to sway whoever is reading. Nice job website design team. I’ll sell you my advice so I can read the article for free.

Comments are closed.